Podcast: Play in new window | Download
Podcast: Play in new window | Download
Podcast: Play in new window | Download
Dr. Peter Rowe is a Professor of Pediatrics at the Johns Hopkins University School of Medicine. He is the inaugural Sunshine Natural Wellbeing Foundation Professor of Chronic Fatigue and Related Disorders and serves as the Director of the Chronic Fatigue Clinic at Johns Hopkins Children’s Center.
His areas of clinical expertise include chronic fatigue syndrome and other disorders characterized by fatigue and orthostatic intolerance. Dr. Rowe and his colleagues were the first to describe the relationship between chronic fatigue syndrome (CFS) and treatable orthostatic intolerance syndromes, as well as the association between Ehlers-Danlos syndrome and CFS.
In this episode, Dr. Rowe and I dive deep into CFS and long Covid for both the parent and the clinician. We set the stage for a better understanding of this complex disorder in order to encourage earlier diagnosis and better therapy.
Please Enjoy,
Dr. M
Podcast: Play in new window | Download
Podcast: Play in new window | Download
Coronavirus Updates #50 and 51 – Listen to the latest data driven perspectives on the pandemic and soon to be endemic COVID world. Omicron, vaccines, boosters, prevention and what is happening now are covered. For the written versions please visit: https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter
Coronavirus Updates #44 and 45 – Listen to the latest data driven perspectives on the pandemic. Vaccine boosters, MIS and what is happening now are covered. For the written versions please visit: https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter
Best,
Dr. M
Podcast: Play in new window | Download
Podcast: Play in new window | Download
Podcast: Play in new window | Download
A few people are asking about the need to vaccinate if you have already had COVID natural illness. What is the story here? Hot off of the press from Cell Reports Medicine, we see: “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based immune responses. SARS-CoV-2 spike binding and neutralizing antibodies exhibit a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. SARS-CoV-2 infection also boosts antibody titers to SARS-CoV-1 and common betacoronaviruses. In addition, spike-specific IgG+ memory B cells persist, which bodes well for a rapid antibody response upon virus re-exposure or vaccination. Virus-specific CD4+ and CD8+ T cells are polyfunctional and maintained with an estimated half-life of 200 days. Interestingly, CD4+ T cell responses equally target several SARS-CoV-2 proteins, whereas the CD8+ T cell responses preferentially target the nucleoprotein, highlighting the potential importance of including the nucleoprotein in future vaccines. Taken together, these results suggest that broad and effective immunity may persist long-term in recovered COVID-19 patients.” (Cohen et. al. 2021)
Read more for COVID #41……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/988-volume-11-letter-33-coronavirus-update-42
Read more for COVID #42……https://www.salisburypediatrics.com/patient-education/dr-magryta-s-newsletter/994-coronavirus-update-42
Happy listening
Dr. M